Hispanic Individuals are Underrepresented in Phase III Clinical Trials for Advanced Liver Cancer in the United States

References

• Jensen E. Measuring racial and ethnic diversity for the 2020 census; 2023. Available from: https://www.census.gov/newsroom/blogs/random-samplings/2021/08/measuring-racial-ethnic-diversity-2020-census.html. Accessed July 21, 2023.
   Google Scholar
• Singh GK, Jemal A. Socioeconomic and racial/ethnic disparities in cancer mortality, incidence, and survival in the United States, 1950–2014: over six decades of changing patterns and widening inequalities. J Environ Public Health. 2017;2017:2819372. doi:10.1155/2017/2819372
   PubMed Web of Science ®Google Scholar
• Miller KD, Ortiz AP, Pinheiro PS, et al. Cancer statistics for the US Hispanic/Latino population, 2021. CA Cancer J Clin. 2021;71(6):466–487. doi:10.3322/caac.21695
   PubMed Web of Science ®Google Scholar
• Stern MC, Fejerman L, Das R, et al. Variability in cancer risk and outcomes within US latinos by national origin and genetic ancestry. Curr Epidemiol Rep. 2016;3:181–190. doi:10.1007/s40471-016-0083-7
   PubMedGoogle Scholar
• Giaquinto AN, Miller KD, Tossas KY, et al. Cancer statistics for African American/Black People 2022. CA Cancer J Clin. 2022;72(3):202–229. doi:10.3322/caac.21718
   PubMed Web of Science ®Google Scholar
• Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 2017;24(3):1073274817729245. doi:10.1177/1073274817729245
   Web of Science ®Google Scholar
• Surveillance, epidemiology, and end results program (SEER); 2017. Available from: https://seer.cancer.gov. Accessed July 21, 2023.
   Google Scholar
• What’s new in liver cancer research?; 2023. Available from: https://www.cancer.org/cancer/liver-cancer/about/new-research.html. Accessed July 21, 2023.
   Google Scholar
• Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. 2020;371:m3544. doi:10.1136/bmj.m3544
   PubMed Web of Science ®Google Scholar
• Martinez Tyson D, Medina-Ramirez P, Flores AM, et al. Unpacking Hispanic ethnicity-cancer mortality differentials among Hispanic subgroups in the United States, 2004–2014. Front Public Health. 2018;6:219. doi:10.3389/fpubh.2018.00219
   PubMed Web of Science ®Google Scholar
• Sangaramoorthy M, Yang J, DeRouen MC, et al. Disparities in hepatocellular carcinoma incidence in California: an update. Cancer Epidemiol Biomarkers Prev. 2020;29(1):79–87. doi:10.1158/1055-9965.EPI-19-0560
   PubMed Web of Science ®Google Scholar
• Ren F, Zhang J, Gao Z, et al. Racial disparities in the survival time of patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma between Chinese patients and patients of other racial groups: a population-based study from 2004 to 2013. Oncol Lett. 2018;16(6):7102–7116. doi:10.3892/ol.2018.9550
   PubMed Web of Science ®Google Scholar
• Al Hadidi S, Mims M, Miller-Chism CN, et al. Participation of African American persons in clinical trials supporting U.S. food and drug administration approval of cancer drugs. Ann Intern Med. 2020;173(4):320–322. doi:10.7326/M20-0410
   PubMed Web of Science ®Google Scholar
• Stewart JH, Bertoni AG, Staten JL, et al. Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities. Ann Surg Oncol. 2007;14(12):3328–3334. doi:10.1245/s10434-007-9500-y
   PubMed Web of Science ®Google Scholar
• Grette KV, White AL, Awad EK, et al. Not immune to inequity: minority under-representation in immunotherapy trials for breast and gynecologic cancers. Int J Gynecol Cancer. 2021;31(11):1403–1407. doi:10.1136/ijgc-2021-002557
   PubMed Web of Science ®Google Scholar
• Aldrighetti CM, Niemierko A, Van allen E, et al. Racial and ethnic disparities among participants in precision oncology clinical studies. JAMA Netw Open. 2021;4(11):e2133205. doi:10.1001/jamanetworkopen.2021.33205
   PubMed Web of Science ®Google Scholar
• Jaffee EM, Dang CV, Agus DB, et al. Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncol. 2017;18(11):e653–e706. doi:10.1016/S1470-2045(17)30698-8
   PubMed Web of Science ®Google Scholar
• U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2022 submission data (1999-2020): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2023. Available from: https://www.cdc.gov/cancer/dataviz. Accessed July 21, 2023.
   Google Scholar
• Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31(28):3517–3524. doi:10.1200/JCO.2012.48.4410
   PubMed Web of Science ®Google Scholar
• Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol. 2013;31(28):3509–3516. doi:10.1200/JCO.2012.47.3009
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31(32):4067–4075. doi:10.1200/JCO.2012.45.8372
   PubMed Web of Science ®Google Scholar
• Zhu AX, Rosmorduc O, Evans TR, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(6):559–566. doi:10.1200/JCO.2013.53.7746
   PubMed Web of Science ®Google Scholar
• Zhu AX, Park JO, Ryoo BY, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16(7):859–870. doi:10.1016/S1470-2045(15)00050-9
   PubMed Web of Science ®Google Scholar
• Cainap C, Qin S, Huang WT, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33(2):172–179. doi:10.1200/JCO.2013.54.3298
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. doi:10.1016/S0140-6736(16)32453-9
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63. doi:10.1056/NEJMoa1717002
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–296. doi:10.1016/S1470-2045(18)30937-9
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796–807. doi:10.1016/S1470-2045(20)30157-1
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38(3):193–202. doi:10.1200/JCO.19.01307
   PubMed Web of Science ®Google Scholar
• D-y O, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015.
   PubMedGoogle Scholar
• Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77–90. doi:10.1016/S1470-2045(21)00604-5
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070. doi:10.1056/EVIDoa2100070
   PubMedGoogle Scholar
• Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995–1008. doi:10.1016/S1470-2045(22)00326-6
   PubMed Web of Science ®Google Scholar
• Flores YN, Datta GD, Yang L, et al. Disparities in hepatocellular carcinoma incidence, stage, and survival: a large population-based study. Cancer Epidemiol Biomarkers Prev. 2021;30(6):1193–1199. doi:10.1158/1055-9965.EPI-20-1088
   PubMed Web of Science ®Google Scholar
• Parada H, Vu AH, Pinheiro PS, et al. Comparing age at cancer diagnosis between Hispanics and non-Hispanic whites in the United States. Cancer Epidemiol Biomarkers Prev. 2021;30(10):1904–1912. doi:10.1158/1055-9965.EPI-21-0389
   PubMed Web of Science ®Google Scholar
• Barzi A, Zhou K, Wang S, et al. Etiology and outcomes of hepatocellular carcinoma in an ethnically diverse population: the multiethnic cohort. Cancers. 2021;13(14):3476. doi:10.3390/cancers13143476
   PubMed Web of Science ®Google Scholar
• Petrick JL, Kelly SP, Altekruse SF, et al. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J Clin Oncol. 2016;34(15):1787–1794. doi:10.1200/JCO.2015.64.7412
   PubMed Web of Science ®Google Scholar
• Hales CM, Carroll MD, Fryar CD, et al. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. JAMA. 2020;324(12):1208–1210. doi:10.1001/jama.2020.14590
   PubMed Web of Science ®Google Scholar
• Bandi P, Minihan AK, Siegel RL, et al. Updated review of major cancer risk factors and screening test use in the United States in 2018 and 2019, with a focus on smoking cessation. Cancer Epidemiol Biomarkers Prev. 2021;30(7):1287–1299. doi:10.1158/1055-9965.EPI-20-1754
   PubMed Web of Science ®Google Scholar
• Lam C, Cronin K, Ballard R, et al. Differences in cancer survival among white and black cancer patients by presence of diabetes mellitus: estimations based on SEER -Medicare-linked data resource. Cancer Med. 2018;7(7):3434–3444. doi:10.1002/cam4.1554
   PubMed Web of Science ®Google Scholar
• Guo A, Pomenti S, Wattacheril J. Health disparities in screening, diagnosis, and treatment of hepatocellular carcinoma. Clin Liver Dis. 2021;17(5):353–358. doi:10.1002/cld.1057
   Google Scholar
• Makarova-Rusher OV, Altekruse SF, McNeel TS, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer. 2016;122(11):1757–1765. doi:10.1002/cncr.29971
   PubMed Web of Science ®Google Scholar
• Endeshaw M, Hallowell BD, Razzaghi H, et al. Trends in liver cancer mortality in the United States: dual burden among foreign- and US-born persons. Cancer. 2019;125(5):726–734. doi:10.1002/cncr.31869
   PubMed Web of Science ®Google Scholar
• Pinheiro PS, Callahan KE, Stern MC, et al. Migration from Mexico to the United States: a high-speed cancer transition. Int J Cancer. 2018;142(3):477–488. doi:10.1002/ijc.31068
   PubMed Web of Science ®Google Scholar
• Pinheiro PS, Callahan KE, Boscoe FP, et al. cancer site-specific disparities in New York, including the 1945–1965 birth cohort’s impact on liver cancer patterns. Cancer Epidemiol Biomarkers Prev. 2018;27(8):917–927. doi:10.1158/1055-9965.EPI-18-0194
   PubMed Web of Science ®Google Scholar
• Ahn JC, Lauzon M, Luu M, et al. Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. Hepatology. 2022;76(6):1649–1659. doi:10.1002/hep.32527
   PubMed Web of Science ®Google Scholar
• Nazha B, Mishra M, Pentz R, et al. Enrollment of racial minorities in clinical trials: old problem assumes new urgency in the age of immunotherapy. Am Soc Clin Oncol Educ Book. 2019;39:3–10. doi:10.1200/EDBK_100021
   PubMedGoogle Scholar
• Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019;5(10):e191870.
   PubMed Web of Science ®Google Scholar
• McDowell A. Why racial diversity in clinical trials is so important. Available from: https://www.antidote.me/blog/why-racial-diversity-in-clinical-trials-is-so-important. Accessed July 21, 2023.
   Google Scholar
• Shebl FM, Capo-Ramos DE, Graubard BI, et al. Socioeconomic status and hepatocellular carcinoma in the United States. Cancer Epidemiol Biomarkers Prev. 2012;21(8):1330–1335. doi:10.1158/1055-9965.EPI-12-0124
   PubMed Web of Science ®Google Scholar